Welcome to our dedicated page for Raphael Pharm SEC filings (Ticker: RAPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is dedicated to SEC-related information for Raphael Pharmaceutical Inc. (RAPH), a clinical-stage biotechnology company developing highly purified, non-psychoactive cannabinoid-based therapies for inflammatory and autoimmune diseases. While no specific SEC filings are listed in the available data, investors typically look to this type of page to review a company’s regulatory disclosures and governance documents.
For a company like Raphael Pharmaceutical, formal SEC reports such as annual reports on Form 10‑K and quarterly reports on Form 10‑Q, when available, can provide detailed discussion of its clinical-stage pipeline, research collaborations, intellectual property strategy, and risk factors related to drug development. Current reports on Form 8‑K, if filed, may describe material events such as clinical milestones, licensing agreements, or patent developments.
Insider transaction reports on Form 4, when present, can offer insight into equity transactions by directors and officers. Proxy statements on Schedule 14A, if filed, may address topics such as executive compensation, board structure, and shareholder proposals. For a biotechnology issuer focused on cannabinoid-based drug candidates, these filings collectively help explain how the company manages its research programs, capital needs, and corporate governance.
On Stock Titan, SEC filings for RAPH, once available from EDGAR, can be paired with AI-powered summaries that highlight key points from lengthy documents. These tools are designed to make it easier to understand complex sections on clinical development plans, intellectual property, and collaboration agreements, while still allowing direct access to the full, official filings for detailed review.
Raphael Pharmaceutical Inc. filed its Q3 2025 10‑Q, reporting continued operating losses and limited liquidity. The company recorded a net loss of $255,000 for the quarter and $1,006,000 for the nine months ended September 30, 2025. There was no revenue.
Costs shifted: R&D expenses fell to $73,000 in Q3 (down 55% year over year) and to $286,000 for the nine months (down 49%), while G&A increased to $178,000 in Q3 and $705,000 for the nine months. Cash used in operations improved to $256,000 for the nine months.
Liquidity is strained: cash was $3,000 as of September 30, 2025, with a stockholders’ deficit of $1,264,000. Current liabilities were $1,271,000 against total assets of $7,000. The company raised $240,000 via share and warrant issuances year‑to‑date and received $38,384 in non‑interest loans from the CEO. Management disclosed substantial doubt about the ability to continue as a going concern absent additional funding.
Operationally, the company announced the completion and U.S. launch of its “RaphaWell” dietary supplement for RA support in August 2025. Shares outstanding were 19,626,418 as of November 13, 2025. Management reported disclosure controls and procedures effective at a reasonable assurance level.
FAQ
What is the current stock price of Raphael Pharm (RAPH)?
What is the market cap of Raphael Pharm (RAPH)?
